A Phase IV Open-Label, Non-Randomized, Multi-Cohort, Multicenter Study in Previously Unvaccinated Immunocompromised Adults to Determine the Immunogenicity and Safety of AZD1222 Vaccine for the Prevention of COVID-19
Latest Information Update: 15 Nov 2022
At a glance
- Drugs AZD 1222 (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms VICTORIA
- Sponsors AstraZeneca
- 10 Nov 2022 Planned primary completion date changed from 28 Dec 2022 to 1 Nov 2023.
- 17 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 27 Sep 2022 Planned End Date changed from 8 Nov 2023 to 1 Nov 2023.